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Abstract: Hypertension remains one of the most prevalent diseases affecting our society, and 
its complications lead the list of causes of mortality all over the world. Most efforts to control the 
disease are unsuccessful, failing in at least two-thirds of affected patients, despite the availability 
of multiple drugs for its treatment. The limited number of medications available for aggressive 
management of hypertensive crises has intensified the search for novel drugs that can achieve 
a rapid decrease in blood pressure without increasing the possible complications. Clevidipine is 
a novel, vasculoselective, dihydropyridine calcium channel blocker characterized by a very fast 
onset and offset of action. Metabolism of clevidipine does not occur in the liver or kidneys, and 
thus there are no restrictions to using clevidipine in patients with hepatic or renal dysfunction. 
This agent has been widely used to reduce blood pressure when oral therapy is not appropriate, 
and its use in the perioperative setting has been shown to be beneficial. This manuscript reviews 
the key characteristics of clevidipine and its role in the management of acute hypertension.
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Introduction
Hypertension remains one of the most prevalent diseases affecting our society, and 
its complications lead the list of causes of mortality all over the world. At least 1% 
of all hypertensive patients present to an emergency department with a hypertensive 
crisis at some point in their lives.1 Defined as a sudden elevation of blood pressure 
(BP) associated with target organ damage, hypertensive emergencies are potentially 
lethal.2
The myocardium is the most commonly affected target organ, but encephalopathy, 
cerebrovascular accidents, acute papilledema, aortic dissection, renal failure, and acute 
pulmonary edema are frequently associated with severe BP elevation.3 Predisposing 
factors for development of a hypertensive crisis include mechanical stress and injury, 
endothelial damage, renin-angiotensin system activation, and oxidative stress.3 The 
predominant insult seems to be a cascade of humoral vasoconstrictors that leads to 
increased vascular resistance, generating stress and damaging the endothelium, which 
activates the coagulation cascade and promotes the deposition of fibrin. These pro-
cesses result in ischemia, oxidative injury, and further release of vasoactive substances 
that perpetuate the destructive cycle, culminating in the multiple organ dysfunction 
that characterizes a hypertensive emergency.4 The majority of patients found to have 
a hypertensive emergency have been previously diagnosed with hypertension and 





Most efforts to control the condition have been   unsuccessful, 
failing in at least two-thirds of affected patients, despite the 
availability of multiple drugs for the   treatment of hyperten-
sion.2 Finding an adequate antihypertensive drug suitable 
for the individual patient, according to his or her personal 
characteristics (ie, race, age, etiology, associated morbidity, 
and concomitant therapies) and the nature of their condition 
(ie, chronic hypertension, acute hypertension, hypertensive 
emergency, or hypertensive urgency) has proven difficult to 
achieve over the last 40 years, leading to an increasing number 
of hypertensive emergencies.6
A common reason for hypertensive emergency is patient 
noncompliance with medical therapy. However, there are 
other potential causes, including stimulant intoxication 
(ie, cocaine, methamphetamines, phencyclidine, etc)7,8 and 
antihypertensive drug withdrawal syndromes (eg, from 
  clonidine and beta-blockers). On rare occasions, patients are 
found to have a pheochromocytoma or another underlying 
condition that triggers the crisis.9
Most patients arriving in emergency departments who 
are found to have severe hypertension, ie, systolic BP 
(SBP) . 160 mmHg or diastolic BP (DBP) . 100 mmHg, do 
not present with acute target organ damage, and are not cases of 
hypertensive emergency, but do present as hypertensive urgency 
cases. In these patients, oral therapy may be the best choice to 
lower BP gradually within 24–48 hours to avoid hypoperfu-
sion caused by an abrupt drop in BP.3 However, patients who 
present as a hypertensive emergency and with target organ 
damage require aggressive management of their BP to limit 
the hypoxic injury already taking place in these organs. For this 
reason, rapid-acting antihypertensive agents that can be easily 
titrated and administered intravenously (IV) are preferred for the 
management of hypertensive crisis. According to the seventh 
report of the Joint National Committee on Prevention,   Detection, 
Evaluation, and Treatment of High Blood Pressure (JNC 7), 
the aim is to bring DBP down by 10%–15%, but by no more 
than 25%, or at least to 110 mmHg within 30 to 60   minutes.2 
Once achieved, the IV medication can be slowly weaned, and 
BP can be maintained with oral therapy. It is important to note 
that hypertensive emergency per se is a clinical diagnosis, and 
the administration of any medication should be appropriate 
to the clinical status of the patient, regardless of the BP val-
ues at the time.10,11 The management of hypertension in these 
settings should be done in an intensive care unit and patients 
should undergo close monitoring to minimize the morbidity and 
mortality associated with abrupt reductions in BP.
A variety of IV antihypertensive drugs can be used, 
depending on the patient’s clinical status (eg, presence of 
liver or kidney failure, pregnancy, or allergies), the target 
organ affected, and the resources available to monitor the 
patient adequately. Labetalol is the most commonly used 
agent (32%) to manage severe hypertension, followed by 
metoprolol (16%), nitroglycerin (15%), hydralazine (15%), 
nicardipine (8%), and sodium nitroprusside (SNP, 6%).12 
Nevertheless, the use of clevidipine in these settings has been 
increasing since its approval in this indication by the US Food 
and Drug Administration (FDA) in 2008, and several trials 
have confirmed its efficacy and safety.
The limited number of medications available for aggres-
sive management of hypertensive crises, eg, in the emergency 
department or during specialized surgical procedures, has 
created a need for newer drugs that provide a rapid decrease 
of BP without increasing the risk of complications. Accord-
ingly, there is continuous ongoing research on antihyperten-
sive drugs that can be easily adapted for use in hypertensive 
emergencies and urgencies. This manuscript reviews the 
key characteristics of clevidipine (Cleviprex®), a novel 
antihypertensive agent, and its role in the management of 
acute hypertension.
Overview of clevidipine
Clevidipine is a novel, vasculoselective calcium channel blocker 
(CCB) of the dihydropyridine type which induces powerful 
vasodilatation in arterioles.6,13 Clevidipine was designed as 
an oil-in-water emulsion containing egg yolk phospholipids, 
soybean oil, and glycerin, and excited the research community 
because of its selectivity and ability to reduce afterload without 
affecting preload.13,14 Clevidipine was the first IV antihyper-
tensive treatment introduced to the market after 10 years of 
research.15 Clevedipine’s effects on human vasculature were 
first studied in the internal mammary artery, and it was found 
to have a considerable vaso-relaxing effect induced by throm-
boxane A2 analog.16
Clevidipine is similar to felodipine in its structure but is func-
tionally closer to nicardipine.17 It is considered unique because 
of its very short duration of action (ie, rapid onset and offset), 
achieved by the incorporation of an additional ester group in the 
molecule.17,18 This results in rapid hydrolysis of the molecule by 
blood and tissue esterases, producing the carboxylic acid metabo-
lite H 152/81. Clevidipine is a racemic mixture of enantiomers, 
ie, R(-)-clevidipine and S(+)-clevidipine, both of which impact 
BP, but the latter contributes to a larger extent at equivalent 
plasma levels.17 Clevidipine has no effects on venous vascular 
tone and its ability to modify afterload prevents it from affecting 
other hemodynamic parameters, including left ventricular filling 
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Pharmacokinetics and 
pharmacodynamics
Immediately after IV infusion, clevidipine is hydrolyzed 
primarily by blood esterases into its inactive metabolites 
(esterases in extravascular tissue also have a moderate role), 
including hemiacetal esters and butyric acid, which do not 
have a relevant effect on any of the CYP450 enzyme.19 
Approximately 99.5% of clevidipine in plasma is bound 
to proteins, and this binding capacity is not concentration-
dependent.18,20,21 Clevidipine is a high clearance drug, 
whereby the kidney is responsible for the elimination of at 
least 60% of the drug and the remainder is eliminated in 
feces.21 Clevidipine goes through the first phase of its elimina-
tion during this first minute after administration, and as much 
as 85%–90% is eliminated at this time. The remainder of the 
drug is metabolized and has a terminal half-life of approxi-
mately 15 minutes.13,21 This unique pattern of metabolism is 
not affected by hepatic dysfunction, and its rapid elimination 
contributes to prompt recovery of normal BP.13
Use of clevidipine for  
perioperative hypertension
Uncontrolled BP is common in the perioperative period, 
and antihypertensive medication is often necessary.22 This 
is especially the case in cardiac surgery, where any sudden 
increase in BP increases the risk of postoperative complica-
tions. An increase in BP means that the myocardium has to 
work harder, thus increasing myocardial oxygen demand, 
which may ultimately lead to an increase in left ventricular 
filling pressure, resulting in pulmonary congestion.23 Sud-
den increases in BP are also responsible for hemorrhage, 
one of the common complications in the postoperative 
period.24
One of the main causes of perioperative hypertension is a 
generalized increase in sympathetic tone that causes vasocon-
striction and in turn increased BP. The ideal antihypertensive 
agent would produce vasodilatation efficiently and rapidly, 
with minimal adverse effects. The usual drugs of choice 
for this purpose are nitroglycerin or SNP, with β-blockers 
and CCBs used in a minority of patients.25 However, since 
the advent of clevidipine, several trials have evaluated the 
safety and efficacy of the drug in this setting. Preliminary 
research gave a glimpse of the efficacy of clevidipine, leading 
to two large randomized, double-blind, placebo-controlled 
trials, ie, ESCAPE 1 and ESCAPE 2, that evaluated the 
use of clevidipine in the pre- and postoperative periods, 
respectively.26,27
ESCAPE-1 in preoperative 
hypertension
The ESCAPE-1 trial included 150 hypertensive patients 
scheduled for cardiac surgery who received either clevidipine 
or placebo (lipid emulsion) via peripheral or central IV infu-
sion over 30 minutes.26 Patients were assessed with a baseline 
echocardiogram, laboratory screening, vital signs record-
ing, and careful monitoring of SBP and DBP. Treatment 
failures were compared between the two groups to evaluate 
efficacy, where treatment failure was defined as an inability 
to achieve at least a 15% reduction in baseline SBP. Further 
assessments included time taken to reach target BP, change 
in mean arterial pressure (MAP), change in heart rate (HR), 
and long- and short-term adverse effects.
This clinical trial was the first to demonstrate the efficacy 
of clevidipine, and showed a significantly lower rate of treat-
ment failure compared with placebo (clevidipine 7.5% versus 
placebo 82.7%, P , 0.0001). The safety of clevidipine was 
evaluated by HR changes and the rate and type of adverse 
effects observed. Surprisingly, both clevidipine and placebo 
were free of HR changes after discontinuation of infusion, 
and the increase in HR observed initially was not substantial. 
Both treatment groups had similar adverse event rates, which 
included pyrexia, atrial fibrillation, acute renal failure, and 
nausea, in descending order. All these adverse events were 
more frequently noted in patients on clevidipine treatment 
but the difference was not statistically significant. Despite 
some limitations, this study demonstrated that clevidipine 
was successful in decreasing SBP by at least 15% from 
baseline in 92.5% of the cases, achieving this within a mean 
of six minutes after infusion.26
ESCAPE-2 in postoperative 
hypertension
The presence of postoperative hypertension is a factor that 
negatively impacts the outcome of surgery and may have 
adverse consequences, including increased risk of stroke, 
renal injury, heart failure, and postoperative bleeding.28 
Despite being a highly modifiable cardiovascular risk factor, 
BP has been found to be extremely hard to control following 
cardiac surgery. After much research concerning the effects 
of elevated BP, it has been shown that increased SBP (essen-
tially when isolated) is a negative predictor and risk factor 
for cardiovascular morbidity.29
Systolic hypertension is the most common cause of 
postoperative hypertension in the elderly, partially due to 





cardiac surgery.30 Arteriosclerosis is a common condition 
in this age group, is exacerbated by hypertension, and is a 
contributor to increased SBP. Another comorbidity associ-
ated with increased SBP is left ventricular hypertrophy, 
which has been found to contribute directly to perioperative 
morbidity.
The need to maintain tight control of BP during and after 
cardiac surgery led to the initiation of the ESCAPE-2 trial to 
evaluate the efficacy of clevidipine in treating postoperative 
hypertension.27 In this trial, 110 of 206 patients recruited met 
the inclusion criteria and received infusions of clevidipine or 
placebo. The design of the study and the variables observed 
in this trial were the same as those in ESCAPE-1. The study 
demonstrated that clevidipine was significantly better than 
placebo in successfully treating postoperative hypertension 
(91.8% success rate with clevidipine versus 20.4% with 
placebo, P , 0.0001). A decrease in SBP was achieved in a 
median of 5.3 minutes with clevidipine. A significantly larger 
decrease in MAP was observed in the clevidipine group at 
2, 5, 10, and 15 minutes after the infusion (mean change in 
MAP -5.7 mmHg versus -0.1 mmHg in the placebo group, 
P = 0.0004). In this study, 94.7% of patients treated with cle-
vidipine reached the target SBP, and only one patient required 
maximal dose titration. No reflex tachycardia was observed 
in the clevidipine group, and the highest median HR recorded 
was 93 beats per minute. Other common adverse effects 
reported were nausea (21.3%), atrial fibrillation (21.3%), and 
insomnia (11.5%), all of which were observed more frequently 
in the clevidipine group. Clevidipine was discontinued in 
one patient because of atrial fibrillation, reported as a nonseri-
ous adverse effect that resolved without sequelae on the same 
day after discontinuing infusion of clevidipine.27
In conclusion, both ESCAPE 1 and ESCAPE 2 demon-
strated that clevidipine was safe and efficacious when used 
in the perioperative setting, predominantly due to its rapid 
onset and offset of action and easy titration.26,27
Clevidipine and sodium 
nitroprusside
As mentioned before, the two agents most commonly used in 
the treatment of postoperative hypertension are nitroglycerin 
and SNP. Both agents are fast-acting vasodilators, but they 
are not very selective and cause some venodilation. Both 
drugs are also known to cause reflex tachycardia, rebound 
hypertension, and tachyphylaxis.
In a double-blind, randomized trial, Powroznyk et al 
compared SNP and clevidipine in the management of 
postoperative hypertension and monitored hemodynamic 
changes in patients undergoing coronary artery bypass graft 
surgery.31 A reason for choosing the setting of cardiac surgery 
was that postoperative hypertension occurs in 30%–50% of 
all patients undergoing the procedure.32 The study recruited 
39 patients of whom 30 met the inclusion criteria, and were 
divided in two groups. One group received clevidipine and a 
SNP   placebo, and the other received SNP and a clevidipine 
placebo. Variables evaluated were the efficacy of the drug in 
controlling BP, the number of dose-rate adjustments neces-
sary to achieve that goal, and the hemodynamic impact of 
the drug. The study results showed no relevant differences 
between the efficacy of clevidipine and that of SNP. There was 
no significant difference between the numbers of dose-rate 
adjustments required for each drug; however, statistically 
significant data were obtained from the monitoring of vital 
signs. The SNP group showed a significantly greater increase 
in HR compared with clevidipine (P , 0.0001). However, 
the propensity of SNP to induce compensatory tachycardia 
is well known. Changes in central venous pressure were 
also more accentuated with SNP, highlighting the marked 
selectivity of clevidipine for arterioles. The study concluded 
that the overall efficacy was similar for both drugs.31
ECLIPSE trial
ECLIPSE was performed to compare clevidipine with SNP, 
nitroglycerin, and nicardipine in the treatment of periopera-
tive hypertension. The study involved three parallel groups 
where clevidipine was compared on a 1:1 basis with one of 
the three other drugs. ECLIPSE was conducted in 61 hospitals 
and included 1512 patients who met the postrandomization 
criteria and were scheduled for cardiac surgery. All drugs 
were administered IV , although nicardipine was restricted 
to the postoperative period because its long half-life makes 
it less suitable for use before and during surgery. The drugs 
involved in the trial were shown to need similar infusion rates 
and volumes to reach the target BP. ECLIPSE demonstrated 
that clevidipine not only achieved superior BP control when 
compared with the other drugs, but also showed a significant 
reduction in 30-day postoperative mortality compared with 
SNP (4.7% versus 1.7%, P = 0.0445). There were no sig-
nificant differences in incidence of cerebrovascular accident, 
heart attack, or kidney damage.33 The use of complementary 
drugs, in particular β-blockers, when the primary drug failed 
to achieve the target was similar among the comparator drugs, 
except for the group treated with SNP, which had a higher 
use of alternative antihypertensive therapy.
Clevidipine was more effective than the comparator 
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BP   excursions compared with the other agents (3.8 versus 
7.8 mmHg × min/hour). Clevidipine also had the narrowest 
SBP range pre- and postoperatively (105–145 mmHg) and 
during surgery (93–135 mmHg). Clevidipine was also shown 
to be more effective than the other study drugs in maintaining 
BP within prespecified ranges for longer periods of time, even 
after modifying target BP thresholds. The study concluded 
that clevidipine was as safe as the other three drugs for use 
in the perioperative setting.
VELOCITY trial
One of the most noteworthy trials performed with clevid-
ipine was the VELOCITY study, a Phase III, open-label, 
single-arm, multicenter study, designed to evaluate the use 
of clevidipine in patients with severe hypertension. The trial 
included 126 patients presenting to an emergency depart-
ment or admitted to an intensive care unit with persistent 
severe hypertension, defined as SBP . 180 mmHg and/or 
DBP . 115 mmHg, assessed on two consecutive occasions 
with an interval of at least 15 minutes in between each mea-
surement. Patients meeting the inclusion criteria underwent 
a physical examination, including urinalysis, funduscopy, 
12-lead ECG, and chest radiography to determine the pres-
ence of acute or chronic target organ damage including at 
least one of the following: abnormal funduscopy with hyper-
tensive changes, congestive heart failure, left ventricular 
hypertrophy, proteinuria or hematuria, neurologic signs, posi-
tive troponin or creatine kinase, or a symptomatic coronary 
syndrome with ischemic ECG changes. Patients were also 
screened for past medical history, baseline laboratory mea-
surements, and medication history. Clevidipine was admin-
istered and titrated according to the prescribing information 
and response of the patient, and after 18 hours oral therapy 
could be administered if needed. During the infusion, BP and 
HR were constantly monitored, with blood samples obtained 
at regular intervals and recording of any adverse events. The 
results revealed that 90.5% of the patients were treated with 
clevidipine only, meaning that other antihypertensives were 
unnecessary to achieve target BP. The desired BP range 
was achieved within the first 30 minutes after infusion in 
88.9% of the patients in a median time of 10.9 minutes, and 
91.3% of the patients underwent successful transition to oral 
therapy. The safety results were also encouraging. The median 
pulse was 82 beats per minute at 3 minutes, and within the 
immediate 30-minute period, the mean increase observed 
was 10 beats per minute compared with baseline. At least 
one adverse effect was observed in 39.7% of patients, with 
8.7% considered serious. Adverse events included   headache, 
nausea, chest discomfort, and vomiting, in descending 
order. During the study, clevidipine was not associated with 
any clinically significant changes in laboratory test results 
(eg, triglyceride levels) or any increased risk of renal injury. 
Overall, the findings of VELOCITY were consistent with 
those encountered in the large trials, and clevidipine was 
once again demonstrated to be a safe and manageable drug 
for treating severe hypertension.12
Indications, dosage,  
and contraindications
Clevidipine is indicated in patients to reduce BP when oral 
therapy is not feasible.34 As noted, clevidipine is administered 
by IV infusion via a central or peripheral line, starting with a 
1–2 mg/hour infusion, doubling the dose at 90-second intervals, 
and then increasing the dose by less than double at intervals of 
5–10 minutes.35 Treatment and amount of clevidipine needed 
may vary from one patient to another, because the titration of the 
drug is dependent on the response and the desired BP. However, 
the majority of patients reach their target BP at 4–6 mg/hour in 
less than 30 minutes after starting the infusion with clevidipine. 
The maximum infusion rate is usually 16 mg/hour, although 
there are insufficient data available for doses $32 mg/hour or 
infusions $72 hours regardless of the dose.36
Clevidipine is packaged in single-use vials of 50 and 
100 mL with a concentration of 0.5 mg/mL, and the vehicle 
is a 20% phospholipid emulsion. The amount of lipids pro-
vided by the infusion of clevidipine is 0.2 g/mL, representing 
2 kcal/mL. For this reason it is recommended that patients do 
not receive more than 1000 mL of clevidipine in 24 hours. 
It is not necessary to adjust the dose in patients with liver 
or renal failure.36
Because of its formulation, clevidipine is contraindicated 
in patients allergic to soybeans, soy products, eggs, or egg 
products. Accordingly, this drug should used with caution 
in patients with abnormalities of lipid metabolism, and lipid 
intake restriction may be required in some patients. Patients 
with severe aortic stenosis should also avoid using clevidipine 
because it can reduce myocardial oxygen delivery as a result 
of significant reduction in afterload. Other contraindications 
of clevidipine include those common to all CCBs, and long-
term monitoring is advised if the patient is not converted to 
oral therapy after using clevidipine.
Other effects of clevidipine
Several experimental models have been used to determine 
the effects of CCBs on the myocardium when administered 





regarding the mechanism by which CCBs achieve myocardial 
protection have been put forward. Activation of potassium 
channels, increase in blood flow to the myocardium during 
reperfusion, and inactivation of oxygen free radicals are now 
well known mechanisms. It is known that both ischemia 
and reperfusion cause tissue damage, and calcium overload 
is one of the most important mechanisms of myocardial 
  dysfunction. Intracellular calcium levels fluctuate throughout 
the stages of myocardial injury, and have been found to be 
high both during the early ischemic period and in the early 
reperfusion phase, contributing to severe cellular injury. 
The mechanisms that trigger the insult mediated by calcium 
are excessive myofilament activation during reoxygenation, 
impaired mitochondrial function followed by a reduction 
in the production of adenosine triphosphate and limitation 
of the metabolic regeneration of the myocyte, and protease 
activation with subsequent tissue damage. Segawa et al dem-
onstrated the beneficial effect of clevidipine infused shortly 
after the initiation of ischemia and just before reperfusion, 
emphasizing the role of calcium in myocardial injury.37
Although not all calcium antagonists work the same way, 
a narrow relationship between CCBs and nitric oxide (NO) 
is evident. NO is a potent mediator of vascular tone, and 
has well known actions, including prevention of platelet 
adherence and a protective effect against superoxide anions. 
Moreover, impairment of the bioavailability of NO is strongly 
related to endothelial dysfunction, which is the common 
event in several cardiovascular diseases.38
In a placebo-controlled study by Gourine et al 38 pigs were 
subjected to a 45-minute ligation of the left anterior descend-
ing coronary artery and administered clevidipine alone, or in 
combination with other vasoactive mediators affecting the 
synthesis and regulation of NO. Variables recorded were 
infarct size, hemodynamic parameters (ie, MAP, HR), and 
endothelial-dependent responses. This study demonstrated that 
clevidipine was cardioprotective when administered directly 
in the coronary vessels during the last 10 minutes of ischemia 
and in the first five minutes of reperfusion. This was indicated 
by a significant reduction of infarct size in clevidipine-infused 
pigs compared with vehicle-infused pigs (-86% in the vehicle 
group versus 59% in the clevidipine group, P , 0.001). More-
over, the cardioprotective effect of clevidipine was strongly 
dependent on the local availability of NO, which was expected 
on the basis of a previous report.39
Conclusions
Clevidipine is a CCB characterized by a very fast onset and 
offset of action, and its initial use was to control hypertensive 
emergencies. It has a unique metabolism, occurring in 
the blood and extravascular tissues by esterases, giving it 
an initial half-life of less than 3 minutes and, because its 
metabolites are inactive, almost null toxicity. Its metabolism 
is also an attribute that ranks clevidipine over other available 
short-acting drugs. Because its metabolism does not occur in 
the liver or in the kidneys, there are no restrictions to using 
clevidipine in patients with hepatic or renal dysfunction. 
Furthermore, clevidipine infusion has a cardioprotective role 
in compromised myocardium.
After 10 years of research and development culminating 
in FDA approval in 2008, clevidipine has been widely used 
to reduce BP when oral therapy is not appropriate. Its use 
in the perioperative setting, mainly in cardiac surgery, has 
been shown to be beneficial compared with the few agents 
previously used for this purpose (eg, SNP and nitroglycerin), 
with a shorter duration of action and a lower incidence of 
adverse effects.
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